Strongbridge Biopharma

Discussion in 'Biotech Startups' started by anonymous, Oct 23, 2017 at 1:22 AM.

  1. anonymous

    anonymous Guest

    Does anyone have a pulse on this company? There’s not a lot out there on the inter webs beyond their website.
     

  2. anonymous

    anonymous Guest

    a 60 year old product with a new name and new indication. Not very exciting and the leadership is shaky.
     
  3. anonymous

    anonymous Guest

    Spot on.
     
  4. anonymous

    anonymous Guest

    Agree. Old products, inexperienced senior leaders, no investors of note. Doesn’t look interesting.
     
  5. anonymous

    anonymous Guest

    Not terribly impressed with Yaffa and the other recruiters.
     
  6. anonymous

    anonymous Guest

    Young company with inexperienced leaders without a track record. Big plus is if you don’t want to leave the area, that’s about it.
     
  7. anonymous

    anonymous Guest

    This sounds fishy. Old repackaged drug made only 2 million in q3 and that's enough to expand the rep count? Company barely has enough capital to stay afloat thru May of next year.
     
  8. anonymous

    anonymous Guest

    Interesting as I looked at it as well. Looks like they were trying to imitate other companies any way they could - move to Ireland, buy an old product and tell a story. Like the offspring of Allergan and Turing without any of the smarts. Agree.
     
  9. anonymous

    anonymous Guest

    Washington Post just trashed this company. Basically said they were the next Turing, and management too cowardly to comment. Good place not to work.
     
  10. anonymous

    anonymous Guest

    Senators now calling for an investigation. Might be a good opportunity to move up after the CEO joins Skrelli in jail.
     
  11. anonymous

    anonymous Guest

    Just curious about jobs in the PA area. But you’d have to be an idiot to work for this company- it will be like trying to get a job after leaving Turing.
     
  12. anonymous

    anonymous Guest

    Boy did you call that one right ! Bunch of criminals.
     
  13. anonymous

    anonymous Guest

  14. anonymous

    anonymous Guest

    Talk about an inept strategy - trying to imitate Martin Skrelli !
     
  15. anonymous

    anonymous Guest

    https://www.washingtonpost.com/news/wonk/wp/2017/12/18/this-old-drug-was-free-now-its-109500-a-year/?utm_term=.89207a0604fe

    https://endpts.com/a-us-senator-calls-out-a-little-biotech-for-price-gouging-but-will-it-change-anything/

    This is not exactly like Turing. Sun Pharma did get a new approval which gave it new exclusivity under US law. That was an investment that the company could recoup and they sold the rights to Strongbridge.

    I'm not discounting the bad optics, but Turing did no research and was actively blocking others from entry. Turing really were just trying to hike the price and get as much cash as possible.

    These guys seem to be working to commercialize the value of the investment made by Sun and then sold to them for a new indication.
     
  16. anonymous

    anonymous Guest

    The drug they are selling and price gouging is basically a generic that they did zero work for. It is in fact the same story as Turing. Somehow I trust the Washington Post.
     
  17. anonymous

    anonymous Guest

    The salesforce has been around for less than a year and there’s already been turnover. Nice salaries, sure but bonuses are on the weak side. And nothing in the pipeline is game changing if that’s what you’re looking for.
     
  18. anonymous

    anonymous Guest

    Thanks. Heard there was turnover. Also saw they basically had a failed capital raise they couldn’t compete!
     
  19. anonymous

    anonymous Guest

    What is going on with the hiring of reps to sell macrilen?
     
  20. anonymous

    anonymous Guest

    Who wants to sell a diagnostic this group of criminals will also try to overprice ??!